We have performed an in-vivo study with the new formulation in an established hair growth model in mice. After application of the highest dose five times a week we observed a clear increase in hair growth. The positive results from the in vivo study are very important since we received concrete evidence that the treatment with the formulation really works, with a demonstrated stimulation of hair growth. In the study we also compared FOL-005 with an established treatment, Minoxidil 5% administrated twice daily, and the results for both treatments were during the main part of the study equal.
Follicum filed a patent application for the new topical formulation during the spring. The formulation is intended for application on the scalp and has demonstrated good hair stimulating effect in an animal model. If the patent application is approved, the protection for FOL-005 will be extended with 8 years. The next step for the formulation is to be tested in the clinical phase II trial on alopecia patients, which is planned to start at the end of 2019.
In the beginning of 2019, Follicum employed two post-doctoral scientists to establish an in-house laboratory for in vitro studies of Follicum’s peptides and the effects on diabetes and its complications.
LUDC (Lund University Diabetes Centre) has been granted a post-doc to study the Mode of Action (MoA) of our diabetes peptides. Dr Chrysostomi Gialeli is the latest addition of resources to Follicum on a post-doc employment to speed up the research with the aim to strengthening the potential of Follicum’s peptides for future diabetes treatment.
Follicum received an official grant of patent from the European Patent Office, EPO regarding the company’s broadened patent application for stimulation of hair growth. With EPO’s grant of the patent there is now broad protection for Follicum’s peptides in Europe until 2032.
Follicum established a Scientific Advisory Board in the diabetes field. The purpose is to strengthen knowledge transfer from academic research to clinical application and commercialization. The Board consists of 5 internationally reputable experts with extensive experience in research into diabetes and its complications.
The Korean patent office (”KIPO”) approved the company’s patent application for stimulation of hair growth. With this approval, Follicum has a patent protection in Korea up to and including year 2032. The patent protects the company’s peptides in general and for stimulation of hair growth in particular.
Follicum received Notice of Allowance from the U.S. Patent Office for method of stimulating hair growth with FOL-005.
Follicum signed a cooperation agreement with Bioglan AB for the production of clinical trial material of Follicum’s new, cream-like formulation of FOL-005 for topical treatment. The formulation will be used in the Phase II clinical trial on hair loss, which is expected to start in the beginning of 2020.
Follicum successfully completed the supplementary toxicology studies that will form the basis of the forthcoming clinical study with the topical formulation of FOL-005.
Follicum’s application for a Eurostars grant comprising the development of a first-in-class treatment for diabetes was approved. Follicum is the coordinator of the project. Other partners include Lund University, Bioassay Labor für biologische Analytik GmbH and Deutsche Diabetes-Forschungsgesellschaft (DDZ).
Follicum signed a collaboration agreement with proDERM for conducting the new clinical trial with a cream-like formulation of FOL-005 to be tested on alopecia patients (patients with hair loss).